Inclusion Criteria:
1. Healthy male participants aged 18-55 (inclusive);
2. Participants with body weight of ≥50 kg (inclusive)) and body mass index (BMI) of 18.5-32.0 kg/m2 (inclusive);
3. Participants who voluntarily sign the written ICF;
4. Participants who are able to communicate well with the investigator and complete the study as per the study protocol;
5. Male participants who agree to use reliable contraceptives (such as abstinence, contraceptive barrier, sterilization surgery) for themselves and their partners (such as birth control pills, contraceptive barrier, injection of the contraceptive medroxyprogesterone acetate or contraception by subcutaneous implantation), and agree not to donate sperm, during the study and within 7 months after infusion of the investigational product.
Exclusion Criteria:
1. Trial participants with a history of or currently having any clinically significant diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematological, immunological, psychiatric and metabolic disorders, or any other diseases that may interfere with the study results, or participants with clinically significant allergic reactions or allergic constitution, angioedema, interstitial pneumonitis or acute respiratory distress syndrome;
2. Participants with abnormal vital signs (systolic blood pressure \< 90 mmHg or \> 140 mmHg, diastolic blood pressure \< 50 mmHg or \> 90 mmHg; heart rate \< 50 bpm or \> 100 bpm) or clinically significant abnormalities in physical examination, ECG and laboratory tests (participant to the judgment of clinicians), and those whose LVEF is beyond the normal range as shown by echocardiography; Adult males with a left ventricular ejection fraction (LVEF) outside the normal reference range of 52% to 72%, as defined by the American Society of Echocardiography (ASE), will be excluded;
3. Any clinically relevant laboratory findings that, in the opinion of the Investigator, would preclude inclusion in the trial; including alanine aminotransferase (ALT) \>1.1 × upper limit of normal (ULN), aspartate aminotransferase (AST) \>1.2 × ULN, bilirubin (total) \>1.5 × ULN. Participants with estimated glomerular filtration rate (eGFR) based on Cockcroft-Gault equation \< 90 mL/min/1.73 m2 will be excluded. If any of these tests are out-of-range, the tests can be repeated once;
4. QT interval corrected for heart rate using Fridericia's correction (QTcF) \> 450 msec.
5. Participants with poor venous access;
6. Participants with a history of allergy to the investigational product (pertuzumab or any of its excipients), or, significant allergy to food, or other substances;
7. Participants treated with anti-HER2 therapy or any antibody or other protein drug targeting the HER2 receptor;
8. Participants who have taken any prescription or OTC drugs, including any herbal, and/or nutritional supplements (e.g. vitamins, mineral supplements or other health products) within 14 days before screening;
9. Use of any monoclonal antibody within 3 months or 5 half-lives (whichever is longer) before administration;
10. Use of investigational drugs within 30 days or 5 half-lives (whichever is longer) or discontinuation of monoclonal antibodies with unknown half-life within 6 months; prior to scheduled administration of the investigational drugs on Day 1 of this study.
